A phase II trial of amonafide in patients with endometrial cancer: A gynecologic oncology group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 4, 1998, Pages 406-407

  Asbury, Robert ^a,e   Blessing, John A ^b   Reid, Gary C ^c   McGuire, William P ^d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c RIVERSIDE METHODIST HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Genesee Hospital   (United States)

Author keywords

Amonafide; Endometrial cancer

Indexed keywords

AMONAFIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMIDES; ISOQUINOLINES; MIDDLE AGED; NAPHTHALIMIDES;

EID: 0031815253     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199808000-00018     Document Type: Article

References (4)

1. Silverberg E, Boring CC, Squires BA. Cancer statistics 1996. CA Cancer J Clin 1996;90:46-62.
2. National Cancer Institute. Benzisoquinolone dione (NSC #308847) [Brochure]. Bethesda, MD: National Cancer Institute, 1984.
3. Brana MF, Castellano JM, Santos A, Vasquez D. Synthesis, cytostatic activity, and mode of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid. Current Chemotherapy 1978;2:6-17.
4. Cancer Therapy Evaluation Program. Minutes of the Phase I working group and the biochemical modulators advisory group. Bethesda, MD: Cancer Therapy Evaluation Program, 1985.